INCB001158 not checked

Incyte Corporation · CB-1158

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
4 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Phase 1: INCB001158 administered orally twice daily at the protocol-defined starting dose, with dose escalation/de-escalation based on protocol-defined toxicity criteria to determine the maximum tolerated dose. INCB001158 is administered in combination with daratumumab SC. Phase 2: INCB001158 administered orally at the recommended dose from Phase 1 either as a monotherapy or in combination with…”In the company’s words, NCT03837509 on ClinicalTrials.gov
Tested for
Colorectal Cancer (CRC) (2 trials), Solid Tumors (2 trials), Relapsed or Refractory Multiple Myeloma, Biliary Tract Cancer (BTC), Endometrial Cancer, Gastroesophageal Cancer (GC), Ovarian Cancer, Metastatic Cancer and 9 more
Main trialPhase 1/2
“The purpose of this study is to evaluate the safety and antitumor activity of INCB001158 in combination with daratumumab SC, compared with daratumumab SC alone, in participants with relapsed or refractory multiple myeloma.”In the company’s words, NCT03837509 on ClinicalTrials.gov
Other names
CB-1158 · Arginase inhibitor

Other drugs for Colorectal Cancer (CRC)

All 392 drugs for Colorectal Cancer (CRC)

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 1/2Terminated 5 Apr 2022 INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Phase 1/2Completed 28 Nov 2022 A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Phase 1Completed 30 Apr 2020 Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Phase 1Completed 14 Dec 2021 A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow INCB001158

Following is part of Solo: you see every change to INCB001158 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in